Emgality offers a specific 300 mg dose for patients with episodic cluster headache1,2

Meet Frank in Emgality bubble

Redefine what’s possible for patients like Frank with Emgality 300 mg1

AGE: 40
CLUSTER HEADACHE FREQUENCY:

  • 1 to 4 times per day during active periods that last 7 weeks, followed by periods (≥3 months) of remission

PATIENT BEHAVIOR

  • Tends to seek medical care during active cluster periods
  • May have already tried other treatment options

aHypothetical patient profile.

For the treatment of patients with episodic cluster headache,

Emgality 300 mg cut weekly cluster headache attacks in half or more for most patients at Week 31

Emgality 300 mg gives your patients a chance at ≥50% reduction in weekly cluster headache attack frequency1

  • 71.4% of patients on Emgality 300 mg (N=49) experienced a ≥50% response from baseline vs 52.6% of patients on placebo (N=57) (p=0.046)

Emgality 300 mg reduced the number of weekly cluster headache attacks by an average of 8.7 vs 5.2 with placebo over Weeks 1 to 3 (baseline: 17.8 vs 17.3) (p=0.036)1

INDICATION
Emgality is indicated for the treatment of episodic cluster headache in adults.

SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Review Episodic Cluster Headache study design

Man crossing arms in Emgality bubble

I avoid thinking about cluster attacks as much as I can, but they are the most painful thing I have ever experienced. Even though I have a routine to cope with attacks, I know I need another option.

— Frank, hypothetical patient with episodic cluster headache


We interviewed Bryan, a real patient on Emgality, to learn how taking the first and only calcitonin gene-related peptide (CGRP) antibody proven to reduce the number of episodic cluster headache attacks has impacted his life.1,2 Watch Bryan’s story here.

bPatients were compensated for their time.


SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Explore the efficacy for Emgality or download savings cardsc for eligible patients

cGovernmental beneficiaries excluded.


References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 10DEC2019